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 Efficacy of Cognitive Behaviour Therapy versus 
Anxiety Management for Body Dysmorphic 
Disorder: A Randomised Controlled Trial 
 David Veale  a, b    Martin Anson  a, b    Sarah Miles  a, b    Maria Pieta  a, b    
Ana Costa  a, b    Nell Ellison  a, b 
 a   Institute of Psychiatry, King’s College London, and  b   South London and Maudsley NHS Foundation Trust,  London , UK 
within the CBT group. There were no differences in outcome 
for those with delusional BDD or depression.  Conclusions: 
CBT is an effective intervention for people with BDD even 
with delusional beliefs or depression and is more effective 
than AM over 12 weeks.  © 2014 S. Karger AG, Basel 
 Introduction 
 Body dysmorphic disorder (BDD) is characterised by 
a preoccupation with perceived defects or flaws in physi-
cal appearance that are either not noticeable or appear 
only slight to others. In addition, the preoccupation must 
be significantly distressing or cause impairment in social, 
occupational or other important areas of functioning. 
The DSM-5 has added a further criterion to the diagnosis 
of BDD, which is that, at some time point during the 
course of the disorder, the individual has performed re-
petitive behaviours (e.g. mirror checking) or mental acts 
(e.g. comparing)  [1, 2] . BDD is more common than previ-
ously recognised, with a prevalence of about 2% in the 
general population  [3, 4] . It is a chronic disorder which 
persists for many years if left untreated  [5] . There is a high 
 Key Words 
 Body dysmorphic disorder · Cognitive behaviour therapy · 
Anxiety management · Randomised controlled trial 
 Abstract 
 Background: The evidence base for the efficacy of cognitive 
behaviour therapy (CBT) for treating body dysmorphic disor-
der (BDD) is weak.  Aims: To determine whether CBT is more 
effective than anxiety management (AM) in an outpatient 
setting.  Method: This was a single-blind stratified parallel-
group randomised controlled trial. The primary endpoint 
was at 12 weeks, and the Yale-Brown Obsessive Compulsive 
Scale for BDD (BDD-YBOCS) was the primary outcome mea-
sure. Secondary measures for BDD included the Brown As-
sessment of Beliefs Scale (BABS), the Appearance Anxiety In-
ventory (AAI) and the Body Image Quality of Life Inventory 
(BIQLI). The outcome measures were collected at baseline 
and week 12. The CBT group, unlike the AM group, had 4 fur-
ther weekly sessions that were analysed for their added val-
ue. Both groups then completed measures at their 1-month 
follow-up. Forty-six participants with a DSM-IV diagnosis of 
BDD, including those with delusional BDD, were randomly 
allocated to either CBT or AM.  Results: At 12 weeks, CBT was 
found to be significantly superior to AM on the BDD-YBOCS 
[β = –7.19; SE (β) = 2.61; p < 0.01; 95% CI = –12.31 to –2.07; 
d = 0.99] as well as the secondary outcome measures of the 
BABS, AAI and BIQLI. Further benefits occurred by week 16 
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rate of psychiatric hospitalisations, suicidal ideation and 
completed suicides  [6, 7] . It is poorly identified in psychi-
atric populations, where patients often do not reveal their 
problem because of shame and stigma or present with 
symptoms of depression, social anxiety or obsessive-
compulsive disorder (OCD) when their main problem is 
BDD  [5, 8] . In addition, many resources are wasted on 
those who undergo dermatological and cosmetic surgery 
 [9–11] .
 Regarding pharmacotherapy of BDD, there are three 
randomised controlled trials (RCT)  [12–14] . Phillips et 
al.  [12] found that a selective serotonergic reuptake in-
hibitor (SSRI), fluoxetine, was more effective than a pla-
cebo, and that delusional BDD made no difference to the 
outcome. Phillips  [14] also showed that adding an anti-
psychotic, pimozide, to an SSRI was no more effective 
than adding a placebo in those who had not responded 
to an SSRI alone. Antipsychotics are therefore not rec-
ommended in the NICE (National Institute for Health 
and Clinical Excellence) guidelines for the treatment of 
BDD  [15, 16] . SSRIs are recommended for moderate-to-
severe BDD, with the proviso that a high rate of relapse 
is likely to occur on their discontinuation  [17] . Howev-
er, the data on relapse rates with discontinuation of 
 SSRIs are very minimal, based on just one chart review 
study.
 There have been three small pilot RCTs of cognitive 
behaviour therapy (CBT) for adults with BDD that have 
demonstrated a greater efficacy of CBT compared with a 
waitlist  [18–20] . However, the participants in the study 
by Rosen et al.  [19] were not that representative as the 
sample contained only women, several of whom who had 
disordered eating, and they were less impaired than those 
seen in psychiatric settings. Furthermore, the therapy was 
delivered in a group format. None of the three RCTs de-
termined whether CBT was effective for delusional BDD 
or comorbid depression. Also, none of these studies con-
tained a comparison treatment to control for attention 
and non-specific therapeutic factors.
 Since these pilot trials, the knowledge of the phenom-
enology of BDD has increased, and we have further devel-
oped a cognitive behavioural model to guide treatment 
 [21, 22] . The aim of this trial was therefore to determine 
whether our CBT that is specific for BDD is more effective 
than a credible non-specific alternative (anxiety manage-
ment, AM) over 12 weeks in treating BDD with or without 
delusion in adults aged 18 years and over. AM (based on 
applied relaxation) was chosen to control for therapist at-
tention and alliance as well as homework. AM is not, how-
ever, a ‘placebo’ – it is an active treatment that is effective 
for generalised anxiety disorder  [23] . It has fared less well 
in previous studies against CBT for OCD  [24] or health 
anxiety. However, AM performed as well as CBT in OCD 
with Asperger’s syndrome  [25] and in multiple somato-
form symptoms  [26] , and in the long term in one study on 
obsessions without prominent compulsions  [27] .
 Objectives 
 In the current trial, we tested the hypotheses that CBT 
would be superior to AM in reducing symptoms of BDD 
at a primary outcome point of 12 weeks. In addition, an 
improved outcome within the CBT group after an extra 4 
sessions of therapy was tested. Further, secondary aims of 
this study were to explore (a) whether CBT was as effec-
tive in those with delusional BDD and depression and (b) 
whether the gains in CBT and AM were maintained at the 
1-month follow-up.
 Subjects and Method 
 Design 
 This was a single-blind stratified (by presence of delusional 
BDD and severity of depression) parallel-group RCT conducted in 
the UK. The allocation ratio used was 1: 1. There were no changes 
to the trial design after its commencement.
 Participants 
 Inclusion Criteria 
 The eligibility criteria for participants were as follows:
 (1)  Have a diagnosis of BDD according to the DSM-IV diagnos-
tic criterion  [1] as their main problem; the DSM-IV was used 
as this was operational at the time the study began; BDD was 
defined as their main problem if it was their reason for refer-
ral to treatment, their symptoms were not explained better by 
any other mental disorder and their clinical outcome mea-
sures were indicative of BDD being their most severe mental 
concern. A trained clinician made the diagnosis on the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders  [28] ; if 
there was comorbidity, there had to be agreement between 
the clinician and the patient that their appearance was their 
main concern. Participants with an additional diagnosis of 
delusional BDD were included if the diagnosis referred to de-
lusional beliefs about being ugly or defective (the DSM-IV 
allows double coding of both BDD and delusional BDD, 
which does not occur in the DSM-5). Other types of somatic 
delusions and non-appearance-related delusions were ex-
cluded 
(2)  Have a total of 24 or more on the Yale-Brown Obsessive Com-
pulsive Scale modified for BDD (BDD-YBOCS)  [29] ; this was 
the equivalent of scoring at least 2 (‘moderate’) on all 12 items; 
(3)  Be aged 18 years or above; 
(4)  Be willing to travel to the treatment centre for weekly sessions; 
D
ow
nl
oa
de
d 
by
: 
88
.1
07
.2
15
.6
5 
- 1
0/
16
/2
01
4 
8:
22
:1
4 
PM
 CBT vs. AM for BDD: An RCT Psychother Psychosom 2014;83:341–353
DOI: 10.1159/000360740
343
(5)  Either not be on psychotropic medication or, if taking medica-
tion, be on a dose that had been kept stable for at least 12 weeks 
prior to randomisation with no plans to increase the dose dur-
ing the course of the study; this was subsequently monitored 
during the study .
 Exclusion Criteria 
 Participants were excluded if they:
 (1)  Had a current or lifetime diagnosis of schizophrenia or schizoaf-
fective or bipolar affective disorder; 
(2)  Had severe self-neglect or suicidal intent that required hospi-
talisation; 
(3)  Had a current diagnosis of alcohol/substance dependence, an-
orexia nervosa or borderline personality disorder that required 
treatment first; 
(4)  Had body image concerns that were primarily related to weight 
and/or shape or fulfilled the criteria for ‘eating disorder not 
otherwise specified’; 
(5)  Were currently receiving any other form of psychotherapy; 
(6)  Had received CBT for BDD in the past 6 months, which was 
judged by the clinician as competently delivered, or 
(7)  Did not have sufficient command of English to participate in 
the therapy and complete rating scales. 
 The recruitment took place between April 2009 and March 
2012 at a single centre, which was an outpatient clinic at the Centre 
for Anxiety Disorders and Trauma at the Maudsley Hospital, 
 London. The centre is part of an Improving Access to Psychologi-
cal Therapies (IAPT) or ‘primary care’ service. It also takes na-
tional referrals (or provides ‘secondary care’ service, where pa-
tients are also under the care of their own local community mental 
health team). It is also part of a nationally funded highly specialised 
service for severe treatment-refractory OCD and BDD (which is a 
‘tertiary care’ service).
 Interventions 
 Two interventions were to be evaluated.
 Cognitive Behaviour Therapy 
 In our trial, this focussed form of psychotherapy consisted of 
12 weeks of individual sessions of 1 h at weekly intervals. It fol-
lowed a treatment manual  [30] . The first stage consisted of engage-
ment in a developmental understanding of the problem and setting 
up an alternative view of the problem to be tested in therapy. Im-
agery rescripting followed for past aversive memories that were 
associated with the onset (e.g. bullying)  [31] . A formulation fur-
ther identified factors that were maintaining the person’s preoc-
cupation and distress relating to perceived ugliness. These includ-
ed understanding the unintended consequences of their safety-
seeking behaviours that maintain the preoccupation and distress 
in the long term. The behaviours were aimed at either (1) threat 
detection and monitoring (e.g. cognitive processes such as self-
focussed attention or behaviours such as mirror checking) or (2) 
preventing feared consequences by avoidance (e.g. comparing or 
camouflaging a perceived defect) or (3) attempts to undo the ap-
pearance concerns (e.g. seeking to undergo a cosmetic procedure). 
The therapist aimed to help individuals to identify their beliefs 
about processes such as ruminating or mirror gazing  [32] , to con-
duct behavioural experiments that tested out their expectations or 
an alternative understanding of the problem and to gradually drop 
the safety-seeking behaviours and test out their fears in situations 
or activities that are avoided. These were done in vivo within and 
between sessions for homework. Self-monitoring and habit rever-
sal was used for any skin picking.
 Anxiety Management 
 The treatment followed a standard protocol  [33] . It was pro-
vided once a week for 12 weeks, with each session lasting 1 h. AM 
was planned to entail a therapeutic alliance, support and home-
work similar to the CBT group. The rationale provided was that 
when triggered, the person would experience a threat and nega-
tive thoughts about their appearance. This, in turn, would lead to 
physical symptoms of anxiety and magnify the perceived threat. 
The treatment consisted of (1) practising progressive muscle re-
laxation and breathing daily, (2) identifying triggers and physical 
symptoms associated with appearance-related anxiety and (3) 
utilising brief muscle relaxation and breathing techniques in trig-
ger situations.
 The aim was to reduce baseline anxiety as well as anxiety in 
trigger situations or regarding their appearance. AM was not given 
for 16 weeks, in contrast to CBT, as the researchers did not con-
sider it feasible to continue treatment for such a length of time.
 After AM, there was a waitlist for 4 weeks, when participants 
were able to cross over into CBT if they still fulfilled the criteria 
for BDD. At the very beginning of treatment, both groups were 
told that after the end of their treatment they would be offered 
another type of treatment, to balance the obligation to provide 
care. Twelve weeks of weekly 1-hour sessions were implemented 
for both treatments as it was considered unethical to deny par-
ticipants receiving AM the more established treatment of CBT for 
a period longer than 12 weeks. Twelve weeks were considered the 
maximum time limit for gains from AM and sufficient to deter-
mine whether CBT was superior to AM. The primary endpoint 
was therefore set at 12 weeks. Further research is required to de-
termine the optimum length of CBT for BDD that may be consid-
ered beyond 12 weeks. For both CBT and AM there was no direct 
targeting of other symptoms such as depression or other comor-
bidity.
 Evaluation of Therapy 
 The participants completed the Credibility/Expectancy Ques-
tionnaire (CEQ) at baseline  [34] . The questionnaire measures the 
credibility and treatment expectancy of the treatment assigned. 
Each subscale has a range of 3–27. A higher score indicates higher 
credibility or expectation for improvement.
 Three therapists with at least 5 years of experience and either a 
doctorate in clinical psychology or accreditation by the British As-
sociation for Behavioural and Cognitive Psychotherapies delivered 
the interventions. All three therapists were crossed to deliver both 
treatments. This was determined by clinician expertise and avail-
ability. They were trained and supervised weekly in the delivery of 
the treatments. The therapy sessions were audio recorded (if con-
sented to in writing), and a random sample of 1 in 10 audiotapes 
was rated blind by three accredited CBT therapists using an adher-
ence rating scale developed for the study in order to measure treat-
ment fidelity and quality. Elements of therapy, such as ‘use of be-
havioural experiments’ (CBT), ‘teaching breathing techniques’ 
(AM), and other non-specific components of both treatments, 
such as ‘agenda setting’, were rated as to whether they were in-
cluded in the treatment sessions. Scores for included components 
of therapy were summed to give a total. In addition, therapist di-
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rectiveness was rated on a 5-point Likert scale ranging from 0 
(‘very non-directive’) to 4 (‘very directive’), and therapeutic rela-
tionship was rated on a 4-point Likert scale from 0 (‘poor’) to 3 
(‘very good’). Independent t tests were conducted on mean scores 
for therapy components, therapist directiveness and therapeutic 
relationship.
 Outcomes 
 Information was collected on age, sex, ethnicity, marital status, 
occupation and comorbid diagnoses, using the Structured Clinical 
Interview for DSM-IV Axis I Disorders. For all participants taking 
an SSRI, an equivalent dose of fluoxetine was calculated (e.g. fluox-
etine 20 mg was equivalent to citalopram 20 mg or sertraline 
50 mg). 
 All outcome measures apart from the CEQ were repeated at 
baseline and week 12 (primary endpoint) in both groups. The CBT 
group also completed measures at 16 weeks, after receiving 4 extra 
treatment sessions. The measures were repeated at the 1-month 
follow-up in both groups. The CEQ was administered once at pre-
treatment.
 The primary outcome measure was the BDD-YBOCS  [29] . 
This is a clinician-rated scale administered by a trained blinded 
assessor. The range is 0–48. Cronbach’s α for the scale is 0.80. Re-
sponse to treatment is defined as a 30% or greater decrease in the 
total BDD-YBOCS score, which best corresponded to ‘much im-
proved’ on the Clinical Global Impression (CGI) scale. In the orig-
inal validation study, this cutoff score produced 1 false negative 
(96% sensitivity), that is, 1 participant who was rated as much or 
very much improved on the CGI was not classified as a responder 
on the BDD-YBOCS using the 30% threshold  [29] .
 The following were secondary outcome measures:
 (1)  Brown Assessment of Beliefs Scale (BABS)  [35] – the BABS is 
a 7-item clinician scale rated by a blinded assessor to measure 
the strength of conviction in a belief (e.g. ‘I am as ugly as the 
Elephant man’); each item is rated from 0 (‘non-delusional be-
lief, or least pathological’) to 4 (‘delusional belief, or most path-
ological’) and the total scores range from 0 to 24; higher scores 
represent an increasing delusionality of beliefs; respondents are 
classified as having delusional BDD beliefs if their total score is 
18 or more, and if they score 4 on the first item, indicating they 
are completely convinced that their belief is accurate 
(2)  Montgomery-Åsberg Depression Rating Scale (MADRS) 
 [36]  – the MADRS is a 10-item clinician scale rated by a blind-
ed assessor to measure symptoms of depression; each item is 
rated on a 7-point Likert scale from 0 (indicating ‘normal’ or 
‘no difficulties’) to 6, and the range is 0–60; higher scores reflect 
a greater symptomatology; a MADRS total score of  ≥ 25 is re-
garded as moderate, and of >31 as severe  [37] 
 The following self-report measures were administered weekly:
 (1)  Appearance Anxiety Inventory (AAI)  [38] – the AAI is a 10-
item self-report questionnaire for measuring the frequency of 
avoidance behaviour and threat-monitoring (e.g. checking, 
self-focussed attention) that are characteristic of a response to 
a distorted body image; each item is scored from 0 (‘not at all’) 
to 4 (‘all the time’), and the range of the total scores is 0–40, 
with higher scores reflecting a greater frequency of the respons-
es; the AAI has a Cronbach’s α of 0.86 
(2)  Patient Health Questionnaire (PHQ)-9 Depression Severity 
 [39] – the PHQ is a 9-item self-report measure of depression; 
each item is scored from 0 (‘not at all’) to 3 (‘nearly every day’), 
and the summed total score ranges from 0 to 27, with higher 
scores reflecting a greater symptomatology of depression; 
Cronbach’s α for the scale is 0.89 
(3)  Generalised Anxiety Disorder (GAD)-7  [40] – the GAD-7 is a 
7-item self-report measure for symptoms of generalised anxi-
ety; each item is scored from 0 to 3, and the summed total score 
ranges from 0 to 21, with higher scores reflecting a greater 
symptomatology; Cronbach’s α for the measure is 0.92 
(4)  Body Image Quality of Life Inventory (BIQLI)  [41, 42] – the 
BIQLI is a 19-item self-report scale that measures the impact of 
body image concerns on a broad range of life domains (e.g. 
sense of self, social functioning, sexuality, emotional well-be-
ing, exercise and grooming); the BIQLI is scored as the average 
numeric score of all the items from –3 (‘very negative effect’) to 
+3 (‘very positive effect’); Cronbach’s α for the scale is 0.95 
 Sample Size 
 A sample size of 20 per group was calculated to give 90% pow-
er and a two-sided 5% significance for detecting a beneficial differ-
ence of 8 and a standard deviation of 7 on the BDD-YBOCS be-
tween CBT and AM. These assumptions were made based on a 
previous RCT of CBT in BDD  [18] and approximate to a reduction 
of 30% on the BDD-YBOCS and clinically significant improve-
ment in BDD symptoms  [29] . There was an anticipated 10% drop-
out rate, giving a planned sample size of 22 per group or 44 in total. 
There were no planned interim analyses or stopping rules.
 Randomisation 
 Sequence Generation 
 Randomisation was conducted via the UKCRC (UK Clinical 
Research Collaboration)-registered King’s Clinical Trials Unit, us-
ing a web-based system. Randomisation was at the level of the in-
dividual participant, by the method of minimisation stratified by 
(1) the presence or absence of delusional beliefs on the BABS and 
(2) either a high (25 or above) or a low score (below 25) on the 
MADRS  [37] . The first 4 patients were randomised using simple 
randomisation to create an initial level of imbalance. The minimi-
sation algorithm contained a 20% random component for subse-
quent patients to maintain prerandomisation allocation conceal-
ment. The patients were told they were being randomised to two 
different types of psychological therapy and that if they wished, 
they could switch to the alternative therapy after 12 weeks.
 Allocation Concealment Mechanism 
 The allocation sequence was concealed from the research asses-
sor. An email confirming the treatment allocation was sent direct-
ly to the therapist.
 Implementation 
 The research assessor enrolled participants in the trial and 
gained written informed consent for their participation in the trial 
as well as treatment.
 Blinding 
 The research assessor administering the observer-rated scales 
was blinded to the group assignment at baseline and 12 weeks. She 
had no access to clinician notes, which were kept in a different of-
fice, and was not involved in the supervision or discussion of treat-
ments. While the blinded assessor was located in the same building 
as the therapists, they worked on separate floors. As all therapists 
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were crossed, should the assessor have been at risk of seeing a pa-
tient entering a therapist’s office, blinding would not have been 
broken.
 Statistical Methods 
 All data were entered into the Statistical Package for the Social 
Sciences (SPSS) version 21 for Windows. The analysis of efficacy 
was based on the ‘intention to treat’, utilising data from those par-
ticipants who provided baseline and follow-up data regardless of 
whether they completed the treatment. To reduce the amount of 
missing data from partially filled-in questionnaires, the average 
score was computed for questionnaires where only 1 item was 
missing. In order to correct for multiple missing-item data for 
questionnaires with 2 or more missing items, and in some cases for 
entire missing measures, multiple imputation was used. The 
group, baseline BDD-YBOCS, MADRS, BABS and AAI scores 
were entered into the model as predictors of missing data, and 30 
imputations were run. In order to assess the baseline equivalence 
of the groups, proportions of categorical variables at baseline (e.g. 
demographics) were compared between groups using Fisher’s ex-
act tests. Values of continuous measures at baseline were com-
pared using the Mann-Whitney U test. The primary and secondary 
effectiveness analysis for both groups was based at 12 weeks. The 
results were summarised by mean differences and corresponding 
95% CI. All measures were two-tailed.
 Linear mixed models were conducted to determine the predic-
tive value of treatment group and/or time on the outcome variable 
scores. These measures had a significance of 5% (two-sided). Re-
peated-measures t tests were then used to determine where sig-
nificant differences occurred. Where more than 1 t test had been 
conducted on each variable, a Bonferroni correction was used to 
decrease the risk of type I error. For the CBT group, the repeated-
measures t tests had a significance level of 1.66%, and the AM 
group had a repeated-measures t test significance level of 2.5%.
 A logistic regression analysis was used on binary outcomes as 
either ‘much improved’ ( ≥ 30% change on the BDD-YBOCS) or 
not recovered. A decrease of 30% or more in the BDD-YBOCS 
score was considered ‘much improved’ on the basis that it is sig-
nificantly correlated with the response of BDD symptoms mea-
sured using the CGI  [29, 43] . We conducted a stepwise multiple 
regression analysis to determine whether delusional beliefs on the 
BABS or severely depressed mood on the MADRS (score of >31) 
predicted a response.
 Ethics 
 The study had ethics approval from the Institute of Psychiatry 
and South London and Maudsley NHS Foundation Trust Ethics 
Committee (NHS REC Ref. No. 09/H0907/9). Neither the original 
study design nor the original treatment length was changed during 
the study.
 Results 
 Figure 1 is a CONSORT flowchart of the numbers of 
participants assessed, allocated to each group, receiving 
the intended treatment, completing the study protocol 
and being analysed for the primary outcome.
 The recruitment took place between April 2009 and 
March 2012. Follow-ups took place between December 
2009 and September 2012. The participants attended 
therapy sessions once a week. The trial ended when all 
participants had completed the follow-up.
 The treatments were acceptable to both groups, with 
no significant difference in the number of dropouts be-
tween the groups (χ 2 test with Yates’ correction: 0.33; p = 
0.56).  Table  1 provides the baseline demographic and 
clinical characteristics for all participants and for each 
group. As a group, they would be regarded as in the 
moderate-to-severe range of BDD. Over half were diag-
nosed as having a delusional BDD, nearly two thirds 
having had a trial of at least 1 SSRI in the past and one 
third having had at least 1 cosmetic procedure in the 
past. A slightly lower range of general comorbidity is 
demonstrated by this sample in comparison with previ-
ous surveys ( table 1 ).
 The CBT group had 21 participants and the AM group 
had 25. There were no significant differences between the 
two groups in the demographics and other baseline vari-
ables. Of note is that both groups rated the credibility of 
the treatment as equally low and had a poor expectancy 
of change. Eighty-three percent desired at least 1 cosmet-
ic or dermatological procedure. Nearly half the partici-
pants were stabilised on an SSRI (either fluoxetine or cita-
lopram or sertraline). There was no significant difference 
between the treatment groups in the frequency of par-
ticipants taking an SSRI or the dose prescribed. Apart 
from the SSRIs, 1 participant in the CBT group was taking 
zopiclone 3.75 mg at night, 1 participant in the AM group 
was taking a selective noradrenergic and serotonergic 
reuptake inhibitor (venlafaxine) 150 mg daily, 1 was tak-
ing St John’s wort 900 mg daily and 1 was taking quetiap-
ine 50 mg daily. There were no changes in medication 
type or dosage prescription throughout the duration of 
the study.
 The main features of preoccupation in the whole 
group, in order of prevalence, were: skin (n = 8; 17.4%), 
face in general (n = 7; 15.2%), nose (n = 7; 15.2%), legs 
(n = 3; 6.5%), body hair (n = 3; 6.5%) and all other con-
cerns (n = 18; 39.2%).
 The blinded ratings of session recordings for the CBT 
group indicated that there was a mean of 15.3 (SD = 4.7) 
components of CBT per session and 0 components of 
AM per session [t (46) = 15.75; p < 0.001]. For the AM 
group there was a mean of 15.60 (SD = 6.60) components 
of AM per session and a mean of 0.21 (SD = 0.50) com-
ponents of CBT per session [t (46) = 11.57; p < 0.001]. 
There were therefore no violations of the condition that 
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CBT should not be used in AM and vice versa. In terms 
of blinded ratings of the therapeutic relationship, CBT 
(mean = 2.42, SD = 0.83) did not differ to AM [mean = 
2.17, SD = 0.64; t (46) = 1.17; p = 0.25]. Equally, for ther-
apist directiveness, CBT (mean = 2.25, SD = 0.68) did not 
differ to AM [mean = 2.38, SD = 0.97; t (46) = –0.51; p = 
0.61].
 Table 2 shows the linear change in dependent variable 
scores from baseline to week 12 and the interaction be-
tween group and time for all outcome measures. There 
was a significant group × time interaction for the primary 
outcome (BDD-YBOCS score) and other body image 
measures (BABS, AAI and BIQLI scores) at week 12. 
There was no group × time interaction for depression 
(MADRS or PHQ-9 score) or general anxiety (GAD-7 
score). A main effect of time predicted BDD-YBOCS and 
AAI scores across both time points. Treatment group 
predicted BIQLI scores.
 Table 3 provides means, SD and effect sizes for each 
group, across measurement points, and the Cohen’s d ef-
fect size between CBT and AM for all outcome measures. 
Large effect sizes of 1 between CBT and AM at 12 weeks 
were found for BDD-YBOCS and AAI scores. In the with-
in-group analysis of CBT there was a significant decrease 
across all the measures (including depression and gen-
eral anxiety) at week 12. For the AM group there was a 
significant decrease only for the BDD-YBOCS and AAI 
scores at week 12.
 Fig. 1. CONSORT flow diagram of participants. 
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 Table 1.  Characteristics of participants and by group
Total
(n = 46)
CBT
(n = 21)
AM
(n = 25)
Statistic
 Median age (IQR), years 30.0 (25.0–36.5) 30.0 (24.5–37.5) 29.0 (25.5–37.0) U = 256, Z = –0.14, p = 0.87
 Sex, n (%)
Male
Female
19 (41.3)
27 (58.7)
9 (42.9)
12 (57.1)
10 (40.0)
15 (60.0)
Fisher’s exact test p = 1
Marital status, n (%)
Single
Married
Separated or divorced
30 (65.2)
12 (26.1)
3 (6.5)
13 (61.9)
8 (38.1)
0 (0.0)
17 (68.0)
5 (20.0)
3 (12.0)
Fisher’s exact test p = 0.35
Ethnicity, n (%)
White
Black
Mixed Black and White
South Asian
37 (80.4)
5 (10.9)
2 (4.3)
2 (4.3)
16 (76.2)
2 (9.5)
2 (9.5)
1 (4.8)
21 (84.0)
3 (12.0)
1 (4.0)
0 (0.0)
Fisher’s exact test p = 0.62
Employment, n (%)
Unemployed
Long-term sick leave
Employed or self-employed
Retired
Student (full time)
Homemaker
14 (30.4)
2 (4.3)
21 (45.7)
1 (2.2)
5 (10.9)
3 (6.5)
3 (14.3)
1 (4.8)
12 (57.1)
0 (0)
3 (14.3)
2 (9.5)
11 (44.0)
1 (4.0)
9 (36.0)
1 (4.0)
2 (8.0)
1 (4.0)
Fisher’s exact test p = 0.22
Referral, n (%)
Local primary care
Secondary care
37 (80.4)
9 (19.6)
17 (81.0)
4 (19.0)
20 (80)
5 (20)
Fisher’s exact test p = 1
Median duration of problem (IQR), years 11.0 (6.75–16.5) 14.0 (8.0–23.0) 10.0 (6.0–15.5) U = 206, Z = –1.25, p = 0.21
Current comorbidity, n (%)
Delusional BDD
Depression
Social phobia
OCD
28 (60.9)
25 (54.3)
20 (43.5)
5 (10.9)
2 (4.3)
12 (57.1)
11 (52.4)
9 (42.9)
1 (4.8)
1 (4.8)
16 (64.0)
14 (56.0)
11 (44.0)
4 (16.0)
1 (4.0)
Fisher’s exact test p = 0.69
MADRS score at baseline, n (%)
Moderate depression (>25)
Severe depression (>31)
12 (26.1)
21 (45.7)
5 (23.8)
9 (42.9)
7 (28.0)
12 (57.1)
Fisher’s exact test p = 0.80
Current SSRI, n (%)
Median prescribed daily SSRI dosage
(IQR), mg
21 (45.7) 
60 (20.0–60.0)
12 (57.1)
40 (32.5–55.0)
9 (36.0)
20 (20.0–60.0)
U = 36.5, Z = –1.3, p = 0.22
Previous CBT for BDD, n (%)
Yes 
No
17 (37.0)
29 (63.0)
8 (38.1)
13 (61.9)
9 (36.0)
16 (64.0)
Fisher’s exact test p = 1
Previous SSRI, n (%)
Yes 
No 
22 (61.1)
14 (38.9)
11 (64.7)
6 (35.3)
11 (57.9)
8 (42.1)
Fisher’s exact test p = 0.74
Desire at least 1 cosmetic procedure, n (%)
Yes
No
36 (83.7)
7 (16.3)
17 (81.0)
4 (19.0)
19 (86.4)
3 (13.6)
Fisher’s exact test p = 0.70
At least 1 past cosmetic procedure, n (%)
Yes
No
15 (33.3)
30 (66.7)
4 (19.0)
17 (81.0)
11 (45.8)
13 (54.2)
Fisher’s exact test p = 0.07
CEQ (range: 3–27)
Median credibility score (IQR)
Median expectancy score (IQR)
5.7 (3.33–7)
3.2 (2.03–7.12)
6.0 (3.17–7.67)
6.0 (1.62–7.71)
5.2 (3.33–6.50)
3.0 (2.26–4.35)
U = 89.5, Z = –0.7, p = 0.94
U = 79.0, Z = –0.6, p = 0.58
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 The number of responders (defined as a decrease of 
30% or more on the BDD-YBOCS) at 12 weeks was 
10/21 (48%) in the CBT group and 3/25 (12%) in the 
AM group [χ 2 (1) = 6.20; p = 0.013]. For the CBT group, 
after 16 sessions, 11/21 (52%) were responders (McNe-
mar’s test: n = 21; exact test: p = 0.25). At the 1-month 
follow-up for the CBT group, all 11 responders (100%) 
had maintained their 30% decrease in BDD-YBOCS 
score (McNemar’s test: n = 21; exact test: p = 1.00). At 
the 1-month follow-up for the AM group, all 3 respond-
ers (100%) had maintained their recovery as well 
(McNemar’s test: n = 25; exact test: p = 1.00). CBT was 
again superior to AM in gradually reducing the cogni-
tive processes and behaviours that are thought to main-
tain BDD on the AAI (see online suppl. fig. 1; for all 
online suppl. material, see www.karger.com/doi/ 
10.1159/000360740).
 Prespecified subgroups of those with comorbid de-
pression or delusional BDD at baseline were compared 
over time. Online supplementary table 1 shows the linear 
change in blinded assessor scores from baseline to week 
12 for the subgroups (depressed vs. non-depressed and 
delusional BDD vs. non-delusional BDD) within both 
treatment groups.
 The interaction time × comorbidity at baseline was not 
significant across both treatment groups for the BDD-
YBOCS. This indicates that the treatment was just as ef-
fective over time for both subgroups. Delusional BDD 
significantly predicted BDD-YBOCS scores in the CBT 
group. Online supplementary table  2 shows outcomes 
with estimated effect sizes for subgroup comparisons at 
baseline and week 12 and baseline to week 16 for CBT. 
Both online supplementary tables 1 and 2 display findings 
with decreased power due to their representation of a 
smaller subgroup.
 Those with delusional BDD at baseline in the CBT 
group had significantly higher baseline scores on the 
BDD-YBOCS than those who did not have delusional 
BDD. This difference was no longer significant by the end 
of treatment, indicating that CBT was associated with a 
large decrease in BDD-YBOCS scores for participants 
with delusional BDD.
 Table 2.  Linear growth models for change in outcomes over time
Growth parameter Baseline to week 12 parame ter estimates
β SE (β) p 95% CI
BDD-YBOCS treatment 4.99 3.24 0.124 –1.36 to 11.34
time –4.81 1.84 <0.01 –8.43 to –1.20
treatment × time –7.19 2.61 <0.01 –12.31 to –2.07
MADRS treatment 1.33 5.02 0.791 –8.51 to 11.16
time –4.06 2.15 0.059 –8.28 to 0.155
treatment × time –2.80 3.12 0.370 –8.91 to 3.32
BABS treatment 3.72 2.76 0.178 –1.69 to 9.14
time –1.04 1.42 0.467 –3.83 to 1.76
treatment × time –4.45 2.11 <0.05 –8.58 to –0.315
AAI treatment 6.98 4.06 0.085 –0.972 to 14.94
time –4.41 2.09 <0.05 –8.53 to –0.287
treatment × time –7.87 2.87 <0.01 –13.50 to –2.24
PHQ-9 treatment 3.14 3.64 0.389 –4.00 to 10.28
time –0.327 1.75 0.852 –3.77 to 3.11
treatment × time –3.64 2.53 0.149 –8.60 to 1.31
GAD-7 treatment 1.08 3.28 0.742 –5.36 to 7.52
time –1.50 1.53 0.330 –4.51 to 1.52
treatment × time –2.83 2.13 0.185 –7.02 to 1.36
BIQLI treatment –1.20 0.564 <0.05 –2.31 to –0.098
time –0.368 0.240 0.125 –0.838 to 0.103
treatment × time 0.908 0.350 <0.01 0.223 to 1.59
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 Finally, there was no difference between the groups in 
terms of treating severe depression. Five out of 9 partici-
pants (56%) in the CBT group who were severely de-
pressed at baseline, and 4/11 (36%) who were severely 
depressed at baseline from the AM group, had recovered 
from depression at week 12 [χ 2 (1) = 1.73; p = 0.19]. Those 
5 from the CBT group remained recovered at week 16 af-
ter their final treatment session (McNemar’s test: n = 21; 
exact test: p = 1.00). At the 1-month follow-up conducted 
for the CBT group, 5 participants remained recovered, 
indicating that the effect of treatment on depression was 
maintained (McNemar’s test: n = 9; exact test: p = 1.00). 
Equally, in the AM group, 4 participants indicated a re-
covery from severe depression at the 1-month follow-up 
(McNemar’s test: n = 21; exact test: p = 1.00).
 A multiple regression analysis was conducted to find 
predictors of BDD-YBOCS outcomes. Duration of BDD, 
depression and strength of beliefs (on the BABS) at base-
line were not significant predictors of BDD-YBOCS out-
comes. There was no harm to or unintended effect on 
participants in either group.
 Discussion 
 This is the first study to examine the efficacy of CBT as 
compared with another credible psychological treatment 
for BDD. The study demonstrated that CBT that is tar-
geted at BDD is more effective than AM after 12 weeks if 
evaluated using specific measures for BDD for the group × 
time interaction. AM also had a significant effect on re-
ducing BDD-YBOCS scores, AAI scores and depression 
over time at week 12, but CBT had a larger effect size than 
AM, which was significant across all the measures. CBT 
was just as effective in those with delusional BDD or in 
those who were significantly depressed. Therefore, CBT 
should not be regarded as only suitable for those with 
good insight or who are not depressed. Overall, the results 
of the current study support previous studies  [18–20] re-
garding the effectiveness of CBT for BDD, but they also 
advance the field, as the current study included an active 
psychological treatment (AM) that was set against CBT, 
whereas previous studies only used waitlist controls and 
did not examine treatment effectiveness in comorbid de-
lusional BDD or depression.
 It may be a concern that the AM group did not show 
within-group improvements in GAD-7 scores, whereas 
the CBT group did. However, AM was not targeting gen-
eralised anxiety and worry symptoms, it was specifically 
aimed at anxiety related to appearance, to be applied for 
use in situations when patients felt particularly anxious 
about their appearance.
 The strengths of the study are that the groups were 
matched prior to randomisation and the comparator 
controlled for the passage of time and therapist attention. 
The treatments were rated as equally credible, the thera-
pists were rated as having an equally good therapeutic al-
liance, and both groups had homework tasks for practice. 
The cohort in the current study showed more severe 
symptoms (in terms of severity on the BDD-YBOCS, the 
proportion who had had a previous treatment with an 
SSRI and the proportion who desired a cosmetic proce-
dure) than those recruited for previous RCTs of CBT ver-
sus a waitlist  [18–20] . The current comorbidity rate was, 
however, slightly lower in this population than in other 
studies.
 There are two previous RCTs of CBT versus a waitlist 
that used the BDD-YBOCS as the main outcome measure. 
The within-group effect size in this study at 16 weeks was 
1.67, which is similar to that in the study by Veale et al. 
 [18] (1.57) and Rabiei et al.  [20] (1.49). In the CBT group, 
the frequency of responders on the BDD-YBOCS (52%) is 
similar to that in a trial of fluoxetine versus a placebo in 
BDD  [12] . The fluoxetine trial, however, had a lower with-
in-group effect size of 1.36 on the BDD-YBOCS. On the 
other hand, open-label case series of SSRIs have found 
response rates of 63–73%  [44] . In general, one should be 
cautious about comparing effect sizes in previous RCTs of 
BDD as the numbers in all these trials were small and the 
participants may have shown less severe symptoms in 
some of the studies than in this trial. Nevertheless, the 
findings strengthen the UK NICE guidelines on BDD in 
recommending CBT for BDD including those with a de-
lusional BDD or depression  [15, 45] .
 The trial included participants from a representative 
population with BDD (e.g. both sexes, varied ages, symp-
toms of features that are common in BDD, and partici-
pants with or without medication and who are likely to 
present in a psychiatric setting). Given the wide variety of 
demographic characteristics and recruitment via stan-
dard routes of referral, it is reasonable to assume that the 
intervention can potentially be generalised to other set-
tings if a therapist can build up experience in treating 
BDD. When considering CBT for BDD, slight caution is 
required in future meta-analyses, as not all forms of CBT 
for BDD are identical. For example, meta-cognitive ther-
apy  [18] as evaluated in a recent trial or CBT for BDD as 
reported by Wilhelm et al.  [46] overlaps with our protocol 
but is based on somewhat different conceptualisations 
and interventions.
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 We do not have sufficient information on the mecha-
nism of change in either group. The AAI score was mea-
sured weekly to identify the frequency of the cognitive 
processes and safety-seeking behaviours that are concep-
tualised to be important in maintaining the preoccupa-
tion, distress and handicap related to a distorted body im-
age in BDD. During CBT, these processes decreased 
steadily – and more than they did in AM – and were as-
sociated with reductions in symptoms of BDD. A much 
larger study would be required to demonstrate that such 
processes may mediate change. The optimum length of 
treatment would appear to be at least 16 sessions. The tra-
jectory of the outcome scores beyond 16 weeks suggests 
that some patients may benefit from more than 20 ses-
sions, especially if one includes modules for depression or 
other comorbidity  [46] . Future protocols of CBT might 
also include loading the frequency of sessions at the be-
ginning of therapy (e.g. twice weekly for the first 4 weeks). 
This would be similar to the original cognitive therapy 
protocol for treating depression  [47] , the rationale being 
to maximise engagement and also improve symptoms of 
depression.
 Limitations 
 The study has a relatively small sample that may over-
estimate the effect size. Although there were no signifi-
cant differences for the CEQ and other measures between 
the groups at baseline, the small sample size may have led 
to a type II error. The analysis of the subsample of depres-
sion and delusional BDD may also be subject to a type II 
error. The small sample size may also have led to the dif-
ficulty in identifying any predictors of outcome. Trials of 
clinical effectiveness with larger sample sizes are there-
fore required. No formal testing of blindness of the rater 
was conducted and our group could be accused of having 
an investigator bias towards CBT. However, we believed 
that requesting the research assessor to test blinding 
would be biased as it may be influenced by her rating of 
the outcome. The study is also limited by not reporting 
reliability data on the directiveness and therapeutic rela-
tionship scales, which may have been biased by measure-
ment error. The study may have benefitted from a stan-
dard quality of life measure alongside the main outcomes 
and reporting on the interrater reliability of the adher-
ence ratings. Delivering 12 sessions of therapy may have 
resulted in less gain being achieved at our primary out-
come. The 12-week duration may have been too brief to 
achieve significant changes in BDD and depression. An 
optimal therapy length may well be between 16 and 24 
sessions. However, the aim of this particular study was to 
demonstrate the specific nature of CBT in comparison 
with AM.
 The design of the study compared unequal lengths of 
treatments as the CBT group received 16 weeks of ses-
sions, whereas the AM group received only 12. However, 
the outcome measures were only compared between the 
groups at 12 weeks. Within-group effects were only ana-
lysed for CBT from 12 to 16 weeks. It would have been 
beneficial to do the same for AM so that implications of 
the findings could go beyond 12 weeks for both interven-
tions, but it was deemed unethical to continue AM for 
longer than 12 weeks (discussed above). Currently, we are 
unable to conclude that there is a higher efficacy of CBT 
in comparison with AM beyond 12 weeks of intervention. 
In addition, follow-up outcome analyses for both the AM 
and CBT groups were only conducted 1  month after 
treatment. It may have been optimal to consider the 
maintenance of the study outcomes over a longer-term 
follow-up period. The research was conducted at a single 
centre with specialist expertise in BDD, and further re-
search is required to determine the generalisability of the 
findings in other settings.
 Further Research 
 The study suggests that gains are maintained at the 
1-month follow-up for the CBT group. Further research 
is required to compare treatments at the same endpoint 
beyond 12 weeks and to determine a long-term follow-up 
of 1 year or more in order to better consider the efficacy 
of treatments. CBT is a complex intervention and there is 
a need to unbundle specific modules such as imagery re-
scripting to determine their effectiveness and contribu-
tion to the package. Although about half our participants 
were already stabilised on an SSRI at enrolment, many 
were not taking a maximum dose. Future controlled trials 
are required to determine whether the outcome of CBT is 
enhanced by an augmentation of SSRI doses to the maxi-
mum tolerated dose. Even though it is gratifying that 
there was a large effect size by 16 weeks and 52% of the 
participants had a significant clinical response, nearly 
half remained non-responders. It may be that a longer or 
more intensive CBT or CBT in a residential setting will be 
more beneficial to some participants. This is not surpris-
ing, given the chronicity of their problems, previous fail-
ure of treatment and frequent comorbidity. Further re-
search is required to develop CBT for this difficult-to-
treat population. Lastly, it would be helpful to determine 
the cost-effectiveness of CBT, whether CBT can be suc-
cessful in adolescents, how long it should optimally be 
delivered in different groups and whether it can be adapt-
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